TN participants: |
Late presenters (CD4 <200 cells/μL and/or ≥1 AIDS‐defining event at baseline) vs non‐late presenters |
97 (82 to 100) [28/29] vs 97 (90 to 100) [70/72] |
p = 1.00a
|
TE participants: |
Female vs male |
97 (89 to 100) [62/64] vs 95 (93 to 97) [435/457] |
p = 0.76a
|
Age ≥50 years vs <50 years |
96 (93 to 98) [251/262] vs 95 (92 to 97) [246/259) |
p = 0.66b
|
Age ≥65 years vs <65 years |
100 (92 to 100) [43/43] vs 95 (93 to 97) [454/478] |
p = 0.25a
|
Black race vs other races |
94 (84 to 99) [48/51] vs 96 (93 to 97) [449/470] |
p = 0.72a
|
Adherence <80% vs ≥80% |
100 (59 to 100) [7/7] vs 95 (92 to 97) [295/310] |
p = 1.00a
|
Adherence <95% vs ≥95% |
93 (81 to 99) [40/43] vs 96 (93 to 98) [262/274] |
p = 0.65a
|
|
Median (Q1, Q3) absolute weight change from baseline to 24M in participants, kg
|
p‐value for change from baseline using sign test
|
TE participants: |
Female |
+0.5 (−1.6, +3.0) [n = 49] |
p = 0.55 |
Male |
+1.3 (−1.0, +4.8) [n = 327] |
p < 0.001 |
Age <50 years |
+1.5 (−0.9, +4.7) [n = 185] |
p < 0.001 |
Age ≥50 years |
+1.0 (−1.0, +4.3) [n = 191] |
p < 0.001 |
Black race |
+0.9 (−1.0, +4.3) [n = 36] |
p = 0.30 |
Other races |
+1.2 (−1.0, +4.4) [n = 346] |
p < 0.001 |
No prior TDF |
+1.0 (−1.0, +4.5) [n = 241] |
p < 0.001 |
Received prior TDF |
+2.0 (0.0, +4.4) [n = 139] |
p < 0.001 |